Table 2 Primary and secondary outcomes of the PORTAL trial

Primary outcomes

 Time to functional recovery, n (days)

 Patients with PDAC who start adjuvant chemotherapy at 8 weeks, n (%)

Secondary outcomes

 Estimated blood loss, ml

 Operative time, min

 Length of hospital stay, days

 30-day morbidity, n (%)

  < Clavien-Dindo grade IIIa

  ≥ Clavien-Dindo grade IIIb

 30-day mortality, n (%)

 90-day mortality, n (%)

 30-day readmission, n (%)

 Reoperation, n (%)

 Quality of life assessment

 Perioperative costs, $

 In PDAC

  Resection margin status, n (%)

  Harvested lymph nodes, n

  Positive lymph nodes, n

  Recurrence, n (%)

  Recurrence site, n (%)

  Recurrence-free survival, months

  Overall survival, months